{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:29:35Z","timestamp":1782570575962,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The glycoprotein IIb\/IIIa antagonist tirofiban has been shown to prevent thromboembolic events during endovascular procedures, but the benefits and risks of its prophylactic early intraprocedural administration for stand-alone coil embolization of acutely ruptured aneurysms are still unclear. We conducted a retrospective single-center analysis of patients treated for aneurysmal subarachnoid hemorrhage with stand-alone coil embolization. Two study cohorts were compared according to the primary prophylactic antithrombotic medication during the procedure: patients receiving only intravenous heparin (HEP) versus patients receiving tirofiban in addition to heparin prior to final aneurysm obliteration (HEP\u2009+\u2009TF). Outcome endpoints were the incidence of angiographically visible thrombus formation or distal embolization, and the incidence of periprocedural intracranial hemorrhage (ICH). Of 204 cases, 159 were prophylactically treated with HEP and 45 with HEP\u2009+\u2009TF. Intraprocedural thromboembolic events were less frequent with HEP\u2009+\u2009TF before and after propensity score matching (PSM) (2.5% vs. 19.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.017). The incidence of ICH and symptomatic ICH did not differ between HEP\u2009+\u2009TF and HEP before and after PSM (20.5% vs. 30.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.29; and 5.1% vs. 4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.88). Early intraprocedural tirofiban administration may be effective in preventing thromboembolic complications during stand-alone coil embolization of acutely ruptured aneurysms without increasing the risk of ICH.<\/jats:p>","DOI":"10.1038\/s41598-024-77354-1","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T15:04:04Z","timestamp":1730473444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Propensity score-adjusted analysis on early tirofiban administration to prevent thromboembolic complications during stand-alone coil embolization of ruptured aneurysms"],"prefix":"10.1038","volume":"14","author":[{"given":"Franziska","family":"B\u00fcrkle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte S.","family":"Weyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimah","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Ridwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Nikoubashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wiesmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"77354_CR1","first-page":"319","volume":"15","author":"D Kocur","year":"2020","unstructured":"Kocur, D. et al. Thromboembolism during coiling of intracranial aneurysms: Predictors and clinical outcome. Wideochir Inne Tech. Maloinwazyjne. 15, 319\u2013328 (2020).","journal-title":"Wideochir Inne Tech. Maloinwazyjne"},{"key":"77354_CR2","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/j.wneu.2019.09.149","volume":"133","author":"N Shimamura","year":"2020","unstructured":"Shimamura, N. et al. Use of preprocedural, multiple antiplatelet medications for coil embolization of ruptured cerebral aneurysm in the acute stage improved clinical outcome and reduced thromboembolic complications without hemorrhagic complications. World Neurosurg. 133, e751\u2013e756 (2020).","journal-title":"World Neurosurg."},{"key":"77354_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00062-022-01206-6","volume":"33","author":"F Gottmann","year":"2023","unstructured":"Gottmann, F., Nikoubashman, O., Hollig, A., Reich, A. & Wiesmann, M. Results of Temporary Stent-assisted Coil Embolization (CATS) for the treatment of wide-neck aneurysms: A 10-year single center experience. Clin. Neuroradiol. 33, 219\u2013226 (2023).","journal-title":"Clin. Neuroradiol."},{"key":"77354_CR4","doi-asserted-by":"publisher","first-page":"21326","DOI":"10.1038\/s41598-021-00872-9","volume":"11","author":"L Sun","year":"2021","unstructured":"Sun, L. et al. Safety and efficacy of prophylactic tirofiban infusion for acute intracranial intraprocedural stent thrombosis. Sci. Rep. 11, 21326 (2021).","journal-title":"Sci. Rep."},{"key":"77354_CR5","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.wneu.2022.08.136","volume":"168","author":"C Bilgin","year":"2022","unstructured":"Bilgin, C. et al. The prophylactic use of glycoprotein 2b\/3a inhibitors in the endovascular treatment of intracranial aneurysms: A systematic review and meta-analysis. World Neurosurg. 168, e50\u2013e66 (2022).","journal-title":"World Neurosurg."},{"key":"77354_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3174\/ajnr.A6996","volume":"42","author":"Y Xiang","year":"2021","unstructured":"Xiang, Y. et al. The prophylactic use of tirofiban versus oral antiplatelet medications in stent-assisted coiling of intracranial aneurysms: A meta-analysis. AJNR Am. J. Neuroradiol. 42, 713\u2013719 (2021).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"77354_CR7","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1038\/s41598-024-53715-8","volume":"14","author":"KC Cho","year":"2024","unstructured":"Cho, K. C., Son, N. H., Gwon, S. H., Choi, J. W. & Jung, W. S. The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume. Sci. Rep. 14, 3353 (2024).","journal-title":"Sci. Rep."},{"key":"77354_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/187152908784533748","volume":"8","author":"JP Winter","year":"2008","unstructured":"Winter, J. P. & Juergens, C. P. The role of tirofiban in the management of coronary artery disease. Cardiovasc. Hematol. Disord Drug Targets 8, 138\u2013146 (2008).","journal-title":"Cardiovasc. Hematol. Disord Drug Targets"},{"key":"77354_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jacc.2009.08.052","volume":"55","author":"G Campo","year":"2010","unstructured":"Campo, G. et al. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: The 3T\/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel). J. Am. Coll. Cardiol. 55, 255\u2013256 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"77354_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","volume":"27","author":"DJ Kereiakes","year":"1996","unstructured":"Kereiakes, D. J. et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high risk patients undergoing coronary angioplasty. J. Am. Coll. Cardiol. 27, 536\u2013542 (1996).","journal-title":"J. Am. Coll. Cardiol."},{"key":"77354_CR11","first-page":"192","volume":"13","author":"M Hashemzadeh","year":"2008","unstructured":"Hashemzadeh, M., Furukawa, M., Goldsberry, S. & Movahed, M. R. Chemical structures and mode of action of intravenous glycoprotein IIb\/IIIa receptor blockers: A review. Exp. Clin. Cardiol. 13, 192\u2013197 (2008).","journal-title":"Exp. Clin. Cardiol."},{"key":"77354_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/neurintsurg-2021-018346","volume":"14","author":"H Takase","year":"2022","unstructured":"Takase, H. et al. Antiplatelet therapy for standalone coiling of ruptured intracranial aneurysms: A systematic review and meta-analysis. J. Neurointerv. Surg. 14, 1207\u20131212 (2022).","journal-title":"J. Neurointerv. Surg."},{"key":"77354_CR13","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/STROKEAHA.115.010049","volume":"46","author":"R von Kummer","year":"2015","unstructured":"von Kummer, R. et al. The Heidelberg bleeding classification: Classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 46, 2981\u20132986 (2015).","journal-title":"Stroke"},{"key":"77354_CR14","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.3346\/jkms.2020.35.e430","volume":"35","author":"JM Wang","year":"2020","unstructured":"Wang, J. M. & Chen, Q. X. Risk factors for intraprocedural rerupture during embolization of ruptured intracranial aneurysms. J. Korean Med. Sci. 35, e430 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"77354_CR15","doi-asserted-by":"crossref","unstructured":"Kline, A. & Luo, Y. PsmPy: A package for retrospective cohort matching in python. In Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 1354\u20131357 (2022).","DOI":"10.1109\/EMBC48229.2022.9871333"},{"key":"77354_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1148\/radiol.10092209","volume":"256","author":"L Pierot","year":"2010","unstructured":"Pierot, L., Cognard, C., Anxionnat, R., Ricolfi, F. & Investigators, C. Ruptured intracranial aneurysms: Factors affecting the rate and outcome of endovascular treatment complications in a series of 782 patients (CLARITY study). Radiology 256, 916\u2013923 (2010).","journal-title":"Radiology"},{"key":"77354_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3109\/02841851.2010.508172","volume":"51","author":"P Jartti","year":"2010","unstructured":"Jartti, P. et al. Early rebleeding after coiling of ruptured intracranial aneurysms. Acta Radiol. 51, 1043\u20131049 (2010).","journal-title":"Acta Radiol."},{"key":"77354_CR18","doi-asserted-by":"publisher","first-page":"1096651","DOI":"10.3389\/fneur.2022.1096651","volume":"13","author":"C Gaudino","year":"2022","unstructured":"Gaudino, C. et al. Incidence of intra-procedural complications according to the timing of endovascular treatment in ruptured intracranial aneurysms. Front. Neurol. 13, 1096651 (2022).","journal-title":"Front. Neurol."},{"key":"77354_CR19","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3389\/fneur.2018.01125","volume":"9","author":"SH Lee","year":"2018","unstructured":"Lee, S. H. et al. Impact of reducing the procedure time on thromboembolism after coil embolization of cerebral aneurysms. Front. Neurol. 9, 1125 (2018).","journal-title":"Front. Neurol."},{"key":"77354_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12874-021-01454-z","volume":"21","author":"D Bottigliengo","year":"2021","unstructured":"Bottigliengo, D. et al. Oversampling and replacement strategies in propensity score matching: A critical review focused on small sample size in clinical settings. BMC Med. Res. Methodol. 21, 256 (2021).","journal-title":"BMC Med. Res. Methodol."},{"key":"77354_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","volume":"2","author":"D Rubin","year":"2001","unstructured":"Rubin, D. Using propensity scores to help design observational studies: Application to the tobacco litigation. Health Serv. Outcomes Res. Methodol. 2, 169\u2013188 (2001).","journal-title":"Health Serv. Outcomes Res. Methodol."},{"key":"77354_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart, E. A. Matching methods for causal inference: A review and a look forward. Stat. Sci. 25, 1\u201321 (2010).","journal-title":"Stat. Sci."},{"key":"77354_CR23","first-page":"1498","volume":"27","author":"WJ van Rooij","year":"2006","unstructured":"van Rooij, W. J., Sluzewski, M., Beute, G. N. & Nijssen, P. C. Procedural complications of coiling of ruptured intracranial aneurysms: Incidence and risk factors in a consecutive series of 681 patients. AJNR Am. J. Neuroradiol. 27, 1498\u20131501 (2006).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"77354_CR24","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.ejrad.2011.11.023","volume":"81","author":"YD Cho","year":"2012","unstructured":"Cho, Y. D. et al. Intra-arterial tirofiban infusion for thromboembolic complication during coil embolization of ruptured intracranial aneurysms. Eur. J. Radiol. 81, 2833\u20132838 (2012).","journal-title":"Eur. J. Radiol."},{"key":"77354_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1591019918758493","volume":"24","author":"YK Ihn","year":"2018","unstructured":"Ihn, Y. K., Shin, S. H., Baik, S. K. & Choi, I. S. Complications of endovascular treatment for intracranial aneurysms: Management and prevention. Interv. Neuroradiol. 24, 237\u2013245 (2018).","journal-title":"Interv. Neuroradiol."},{"key":"77354_CR26","first-page":"1326","volume":"27","author":"R Bruening","year":"2006","unstructured":"Bruening, R. et al. Intraprocedural thrombus formation during coil placement in ruptured intracranial aneurysms: Treatment with systemic application of the glycoprotein IIb\/IIIa antagonist tirofiban. AJNR Am. J. Neuroradiol. 27, 1326\u20131331 (2006).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"77354_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/00005344-200304000-00011","volume":"41","author":"M Moser","year":"2003","unstructured":"Moser, M., Bertram, U., Peter, K., Bode, C. & Ruef, J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J. Cardiovasc. Pharmacol. 41, 586\u2013592 (2003).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"77354_CR28","first-page":"2062","volume":"24","author":"J Klisch","year":"2003","unstructured":"Klisch, J., Weyerbrock, A., Spetzger, U. & Schumacher, M. Active bleeding from ruptured cerebral aneurysms during diagnostic angiography: Emergency treatment. AJNR Am. J. Neuroradiol. 24, 2062\u20132065 (2003).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"77354_CR29","first-page":"355","volume":"53","author":"T Hovig","year":"1968","unstructured":"Hovig, T., Dodds, W. J., Rowsell, H. C. & Mustard, J. F. The transformation of hemostatic platelet plugs in normal and factor IX deficient dogs. Am. J. Pathol. 53, 355\u2013373 (1968).","journal-title":"Am. J. Pathol."},{"key":"77354_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.surneu.2006.03.030","volume":"66","author":"T Ishikawa","year":"2006","unstructured":"Ishikawa, T. et al. How does spontaneous hemostasis occur in ruptured cerebral aneurysms? Preliminary investigation on 247 clipping surgeries. Surg. Neurol. 66, 269\u2013275 (2006)","journal-title":"Surg. Neurol."},{"key":"77354_CR31","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1136\/neurintsurg-2015-012055","volume":"8","author":"XD Liang","year":"2016","unstructured":"Liang, X. D. et al. Safety and efficacy of a new prophylactic tirofiban protocol without oral intraoperative antiplatelet therapy for endovascular treatment of ruptured intracranial aneurysms. J. Neurointerv. Surg. 8, 1148\u20131153 (2016).","journal-title":"J. Neurointerv. Surg."},{"key":"77354_CR32","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"M Valgimigli","year":"2009","unstructured":"Valgimigli, M. et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in patients showing resistance to aspirin and\/or resistance to Clopidogrel study. Circulation 119, 3215\u20133222 (2009).","journal-title":"Circulation"},{"key":"77354_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/JBM.S7236","volume":"1","author":"G Campo","year":"2010","unstructured":"Campo, G. et al. Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: Role of tirofiban. J. Blood Med. 1, 61\u201369 (2010).","journal-title":"J. Blood Med."},{"key":"77354_CR34","first-page":"597","volume":"113","author":"O Kuss","year":"2016","unstructured":"Kuss, O., Blettner, M. & Borgermann, J. Propensity score: An alternative method of analyzing Treatment effects. Dtsch. Arztebl. Int. 113, 597\u2013603 (2016).","journal-title":"Dtsch. Arztebl. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77354-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T15:06:02Z","timestamp":1730473562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77354"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77354-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martin Wiesmann has the following disclosures: Consultancy: Stryker; Payment for lectures: Bracco, Medtronic, Siemens, Stryker; Educational Presentations: Bracco, Codman, Medtronic, Phenox, Siemens; has received grants for research projects or educational exhibits from Ab medica, Acandis, Bracco Imaging, Cerenovus, Kaneka Pharmaceuticals, Medtronic, Mentice AB, Microvention, Phenox, Siemens Healthcare and Stryker Neurovascular.Omid Nikoubashman has the following disclosures: Grants: Stryker Payment for lectures: Stryker, Phenox and Werfen.Hani Ridwan has the following disclosures: Consultancy: ThrombX Medical Inc. All other authors had no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26350"}}